- Home
- KR vs ROIV Comparison
KR vs ROIV Comparison
Compare KR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KR | ROIV |
|---|---|---|
| Founded | 1883 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 28.7B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KR | ROIV |
|---|---|---|
| Price | $63.31 | $34.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $68.32 | $48.27 |
| AVG Volume (30 Days) | ★ 7.3M | 6.4M |
| Earning Date | 12-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $147,642,000,000.00 | $8,260,000.00 |
| Revenue This Year | $2.08 | $530.75 |
| Revenue Next Year | $1.31 | $685.92 |
| P/E Ratio | $25.09 | ★ N/A |
| Revenue Growth | ★ 0.35 | N/A |
| 52 Week Low | $54.15 | $16.89 |
| 52 Week High | $76.58 | $42.50 |
Technical Indicators
Market Signals| Indicator | KR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 39.36 |
| Support Level | $55.24 | $33.15 |
| Resistance Level | $65.11 | $37.59 |
| Average True Range (ATR) | 1.47 | 1.15 |
| MACD | 0.38 | -0.29 |
| Stochastic Oscillator | 82.60 | 23.01 |
Price Performance
Historical ComparisonAbout KR Kroger Company (The)
Founded in 1883, Kroger is the largest pure-play supermarket operator in the United States, operating roughly 2,700 stores across more than 30 banners. Kroger's business is primarily grocery-led (roughly 79% of sales), spanning fresh food and private-label offerings, complemented by fuel centers (9%) and pharmacies (12%). The firm also generates income from advertising, data analytics, and manufacturing.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.